Lampalizumab

Summary

Lampalizumab (CHEMBL2109408) is a phase-3 clinical-stage antibody targeting CFD; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (CFD)
• Indications: 1 condition
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109408
Name	Lampalizumab
Type	Antibody
Max phase	3

Also known as: AFD, Anti-fD, FCFD-4514S, FCFD4514S, Lampalizumab, RG-7417, RG7417, Sn578b8z9q, anti-FACTOR-D, LAMPALIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CFD	complement factor D	Binding	10.7	0.7%	P00746

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CFD.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Platelet degranulation	1	CFD
Alternative complement activation	1	CFD
Neutrophil degranulation	1	CFD

Dominant GO biological processes

GO term	Targets
proteolysis	1
complement activation	1
complement activation, alternative pathway	1
response to bacterium	1
zymogen activation	1
protein maturation	1
immune system process	1
innate immune response	1

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02247479	PHASE3	TERMINATED	A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT02247531	PHASE3	TERMINATED	A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT02745119	PHASE3	TERMINATED	Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)
NCT01229215	PHASE2	COMPLETED	A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
NCT01602120	PHASE2	TERMINATED	An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
NCT02288559	PHASE2	COMPLETED	A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
NCT00973011	PHASE1	COMPLETED	A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
DANICOPAN	ChEMBL + PubChem	Phase 4 (approved)	CFD
Iptacopan	PubChem	Approved	CFD